drugset
drugset / Trial / NCT00132028

Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma

NCT00132028 ↗

Phase 2 Completed 27 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well vorinostat works in treating patients with relapsed or refractory advanced Hodgkin's lymphoma. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2005-09
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Vorinostat Small molecule — Oral

Indications

Hodgkin's lymphoma, lymphocytic depletion Hodgkin's lymphoma, lymphocytic-histiocytic predominance Hodgkin's lymphoma, mixed cellularity adult nodular lymphocyte predominant Hodgkin lymphoma nodular sclerosis classical Hodgkin lymphoma